Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. 1993

J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
Department of Nephrology, University of Rouen, France.

The pharmacokinetics of a single 100 mg oral dose of lamotrigine, a new anticonvulsant drug, were studied in six healthy volunteers and in twenty patients with various degrees of renal impairment. Six of these patients were regularly haemodialysed. Lamotrigine concentrations in plasma and urine were measured by the HPLC method. The mean peak plasma concentrations of lamotrigine, tmax, volume of distribution and total clearance were not significantly modified by the degree of renal impairment. The elimination half-life of lamotrigine was approximately 25 h in subjects with normal renal function and 50 h in uraemic patients. These are very large variations in uraemic patients and the results were not statistically significant. Renal clearance of lamotrigine is significantly reduced. Urinary elimination of unchanged and conjugated lamotrigine was reduced in uraemic patients. Thus it seems necessary to treat carefully patients with a very severe renal insufficiency since very large variations in pharmacokinetics were found. A 100 mg oral dose every two days is recommended if creatinine clearance is below 10 ml/min. Haemodialysis shortened the elimination half-life from 59.6 +/- 28.1 h during the interdialysis period to 12.2 +/- 6.4 h during the dialysis period; 17% of the dose was extracted by haemodialysis.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D005965 Glucuronates Derivatives of GLUCURONIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the 6-carboxy glucose structure. Glucosiduronates,Glucuronic Acids,Acids, Glucuronic
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077213 Lamotrigine A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER. 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine,3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine,BW-430C,Crisomet,Labileno,Lamictal,Lamiktal,BW 430C,BW430C

Related Publications

J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
July 1979, The Journal of antimicrobial chemotherapy,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
April 1980, British journal of clinical pharmacology,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
February 1985, British journal of clinical pharmacology,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
January 1987, European journal of clinical pharmacology,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
April 1985, Journal of clinical pharmacology,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
November 1977, European journal of clinical pharmacology,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
July 1999, Clinical therapeutics,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
January 2005, Arzneimittel-Forschung,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
April 1994, Antimicrobial agents and chemotherapy,
J P Fillastre, and A M Taburet, and A Fialaire, and I Etienne, and R Bidault, and E Singlas
February 1979, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!